Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

Genetics in Medicine

Volumn 9, Issue 12, 2007, Pages 826-835

  Thakur, Mugdha ^a   Grossman, Iris ^b   McCrory, Douglas C ^b   Orlando, Lori A ^b   Steffens, David C ^a   Cline, Kathryn E ^b   Gray, Rebecca N ^b   Farmer, Jennifer ^a   DeJesus, Georgette ^a   O'Brien, Cara ^b   Samsa, Gregory ^b   Goldstein, David B ^b   Matchar, David B ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

CYP450; Depression; Evidence based medicine; Pharmacogenetics; SSRI

Indexed keywords

CITALOPRAM; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DATA BASE; DECISION MAKING; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MEDLINE; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; EVIDENCE-BASED MEDICINE; GENETIC SCREENING; GENOTYPE; HUMANS; MEDLINE; POLYMORPHISM, GENETIC; REPRODUCIBILITY OF RESULTS; SEROTONIN UPTAKE INHIBITORS; VARIATION (GENETICS);

EID: 37349057480     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31815bf98f     Document Type: Review

References (85)

1. Kessler RC, Berglund P, Demler O, Jin R, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.
2. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
4. MacGillivray S, Arroll B, Hatcher S, Ogston S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003;326:1014.
5. Song F, Freemantle N, Sheldon TA, House A, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306:683-687.
6. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154:963-969.
7. Beasley CM Jr, Bosomworth JC, Wernicke JF. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24.
8. Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985;28:553-557.
9. Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? J Clin Psychiatry 1992;53:272-277.
10. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299.
11. Dufour H, Bouchacourt M, Thermoz P, Viala A, et al. Citalopram - a highly selective 5-HT uptake inhibitor in the treatment of depressed patients. Int Clin Psychopharmacol 1987;2:225-237.
12. Fichtner CG, Jobe TH, Braun BG. Possible therapeutic window for serotonin reuptake inhibitors. J Clin Psychiatry 1994;55:36-38.
13. Kelly MW, Perry PJ, Holstad SG, Garvey MJ. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989;11:165-170.
14. Kuhs H, Schlake HP, Rolf LH, Rudolf GA. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatr Scand 1992;85:364-369.
15. Laursen AL, Mikkelsen PL, Rasmussen S, Le Fevre Honore P. Paroxetine in the treatment of depression - a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985;71:249-255.
16. Montgomery SA, Baldwin D, Shah A, Green M, et al. Plasma-level response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 1990;(suppl 1):S71-S75.
17. Tasker TC, Kaye CM, Zussman BD, Link CG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989;350:152-155.
18. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004;59:5-12.
19. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005;33:262-270.
20. Mandrioli R, Forti GC, Raggi MA. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Curr Drug Metab 2006;7:127-133.
21. Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999;59:298-309.
22. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000;28:1187-1191.
23. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-243.
24. Bogni A, Monshouwer M, Moscone A, Hidestrand M, et al. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol In Vitro 2005;19:621-629.
25. Cai WM, Nikoloff DM, Pan RM, de Leon J, et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J 2006;6:343-350.
26. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-349.
27. Wang JH, Liu ZQ, Wang W, Chen XP, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001;70:42-47.
28. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006;6:277-286.
29. Roche Molecular Systems, Inc. US Food and Drug Administration 510(k) Substantial Equivalence Determination Decision Summary for Roche AmpliChip CYP450 microarray for identifying CYP2D6 genotype (510(k) Number k042259). December 2004. Available at: www.fda.gov/cdrh/reviews/k042259.pdf. Accessed April, 19 2006.
30. Roche Molecular Systems, Inc. US Food and Drug Administration 510(k) Substantial Equivalence Determination Decision Summary for Roche AmpliChip CYP450 microarray for identifying CYP2C19 genotype (510(k) Number k043576). January 2005. Available at: www.fda.gov/cdrh/reviews/k043576.pdf. Accessed April 19, 2006.
31. Matchar DB, Thakur ME, Grossman I, McCrory DC, et al. Testing for Cytochrome P450 Polymorphisms in Adults with Non-Psychotic Depression Treated with Selective Serotonin Reuptake Inhibitors (SSRIs). Evidence Report/Technology Assessment No. 146. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 07-E002. Rockville, MD: Agency for Healthcare Research and Quality. January 2007. Available at: http://www.ahrq.gov/downloads/pub/evidence/pdf/cyp450/cyp450.pdf. Accessed September 18, 2007.
32. Centers for Disease Control and Prevention. ACCE Model for Evaluation of Genetic Testing. Available at: www.cdc.gov/genomics/gtesting/ACCE.htm. Accessed April 6, 2007.
33. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001). Available at: www.cebm.net/ levels_of_evidence.asp#levels. Accessed April 21, 2006.
34. Kotz S, Johnson NL, Read C. Encyclopedia of statistical sciences. Vol. 4: Icing the tails-limit theorems. New York: Wiley; 1983:352-354.
35. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E, et al. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000;46(8 Pt 1):1072-1077.
36. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003;22:476-485.
37. Neville M, Selzer R, Aizenstein B, Maguire M, et al. Characterization of cytochrome P450 2D6 alleles using the Invader system. Biotechniques 2002;(suppl):34-38, 40-43.
38. Soderback E, Zackrisson AL, Lindblom B, Alderborn A. Determination of CYP2D6 gene copy number by pyrosequencing. Clin Chem 2005;51:522-531.
39. Stamer UM, Bayerer B, Wolf S, Hoeft A, et al. Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 2002;48:1412-1417.
40. Eriksson S, Berg LM, Wadelius M, Alderborn A. Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev Technol 2002;1(1 Pt 1):49-59.
41. Weise A, Grundler S, Zaumsegel D, Klotzek M, et al. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab 2004;50:141-148.
42. Muthiah YD, Lee WL, Teh LK, Ong CE, et al. A simple multiplex PCR method for the concurrent detection of three CYP2C8 variants. Clin Chim Acta 2004;349:191-198.
43. Wu X, Zhou Y, Xu S. Detection of CYP I A1 polymorphisms with a colorimetric method based on mismatch hybridization. Clin Chim Acta 2002;323:103-109.
44. Liu ZQ, Cheng ZN, Huang SL, Chem XP, et al. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol 2001;52:96-99.
45. Ozdemir V, Tyndale RF, Reed K, Herrmann N, et al. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol 1999;19:472-475.
46. Yu BN, Chen GL, He N, Ouyang DS, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003;31:1255-1259.
47. Yoon YR, Cha IJ, Shon JH, Kim KA, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 2000;67:567-576.
48. Berle JO, Steen VM, Aamo TO, Breilid H, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004;65:1228-1234.
49. Charlier C, Broly F, Lhermitte M, Pinto E, et al. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003;25:738-742.
50. Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001;21:330-334.
51. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329-336.
52. LLerena A, Dorado P, Berecz R, Gonzalez AP, et al. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004;59:869-873.
53. Murphy GM Jr., Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-1835.
54. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, et al. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003;58:659-661.
55. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 2004;60:553-557.
56. Scordo MG, Spina E, Dahl ML, Gatti G, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005;97:296-301.
57. Stedman CA, Begg EJ, Kennedy MA, Roberts R, et al. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002;17:187-190.
58. Ueda M, Hirokane G, Morita S, Okawa M, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:486-491.
59. Sindrup SH, Brosen K, Gram LF, Hallas J, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-287.
60. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-121.
61. Rau T, Wohlleben G, Wuttke H, Thuerauf N, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75:386-393.
62. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 2003;167:443-448.
63. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004;59:803-807.
64. Cravchik A, Goldman D. Neurochemical individuality: genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry 2000;57:1105-1114.
65. Allgulander C, Nilsson B. A prospective study of 86 new patients with social anxiety disorder. Acta Psychiatr Scand 2001;103:447-452.
66. Roberts RL, Mulder RT, Joyce PR, Luty SE, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004;19:17-23.
67. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochromeP4502d6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 2006;31:825-831.
68. Chen S, Chou WH, Blouin RA, Mao Z, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-534.
69. Kirchheiner J, Nickchen K, Bauer M, Wong ML, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-473.
70. Serretti A, Artioli P, Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 2005;15:61-67.
71. Serretti A, Cusin C, Rossini D, Artioli P, et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004;129:36-40.
72. Smits KM, Smits LJ, Schouten JS, Stelma FL, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004;9:433-441.
73. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-590.
74. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-511.
75. Kim DK, Lim SW, Lee S, Sohn SE, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215-219.
76. Kato M, Ikenaga Y, Wakeno M, Okugawa G, et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005;20:151-156.
77. Yoshida K, Takahashi H, Higuchi H, Kamata M, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004;161:1575-1580.
78. Serretti A, Zanardi R, Rossini D, Cusin C, et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001;6:586-592.
79. Ham BJ, Lee MS, Lee HJ, Kang RH, et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 2005;15:299-301.
80. Peters EJ, Slager SL, McGrath PJ, Knowles JA, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-889.
81. Serretti A, Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 2004;4:233-244.
82. McMahon FJ, Buervenich S, Charney D, Lipsky R, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-814.
83. Anonymous. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157(suppl 4):1-45.
84. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 7 August 2007;Epub ahead of print. Available at: http://dx.doi.org/10.1038/sj.tpj. 6500477. Accessed September 18, 2007.
85. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-1632.